Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Hisse Senetlerindeki Sıralama #39071
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Hisse Fiyatı
$0.0568
Son senkronizasyon: 2026-08-13
Piyasa Değeri
$661.36K
Değişim (1 gün)
11.37%
Değişim (1 yıl)
-5.33%
Ülke
US
Ticaret Hepion Pharmaceuticals, Inc. (HEPA)

Kategori

Hepion Pharmaceuticals, Inc. (HEPA) için P/B oranı
2026 itibarıyla P/B oranı TTM: 0
Hepion Pharmaceuticals, Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 0'dir. 2026 yılının sonunda şirketin P/B oranı 0 idi.
Hepion Pharmaceuticals, Inc. için P/B oranı geçmişi 2026 - 2026 arası
Her yılın sonunda P/B oranı
Yıl P/B Oranı Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için P/B oranı
Şirket P/B Oranı P/B Oranı Farkı Ülke
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE